Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma

the ONA take:

According to results presented at the 20th Congress of the European Hematology Association, researchers have found that patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone if they have received at least two prior treatment regimens, including an immunomodulatory agent and bortezomib.

The subgroup analysis, which included 147 patients, demonstrated a 12.5-month progression-free survival for patients who had received at least 2 prior regimens and received panobinostat compared with a progression-free survival of 4.7 months with placebo.

The overall study showed a 3.9-month improvement in median progression-free survival with panobinostat versus placebo.

"Together, these data identify the subgroup of patients with relapsed or relapsed and refractory [multiple myeloma] who benefits most with panobinostat-bortezomib-dexamethasone," Dr. Hermann Einsele, director of the Medical Clinic at University of Wurzberg in Germany said. "The findings support the recent [Food and Drug Administration] approval of the panobinostat combination in [multiple myeloma] patients who received ≥2 prior regimens, including IMiDs and bortezomib."

Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma
Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.
New findings demonstrate that patients with relapsed or relapsed and refractory multiple myeloma derive the largest benefit from panobinostat combination therapy if they have received ≥2 prior regimens, including bortezomib and an immunomodulatory drug.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs